Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Recent Patents Awarded to OSU, Santaris, Venganza, and More


Title: Methods for Diagnosing Lung Cancer using microRNAs

Patent Number: 8,580,500

Filed: Feb. 28, 2012

Lead Inventor: Carlo Croce, Ohio State University

The invention, the patent's abstract states, provides "novel methods and compositions for the diagnosis and treatment of solid cancers. The invention also provides methods of identifying inhibitors of tumorigenesis."

Title: Inhibitory RNA for Modulating the Molecular Function of ZFAT Gene

Patent Number: 8,580,562

Filed: Sept. 8, 2008

Lead Inventor: Senji Shirasawa, Fukuoka University

The invention, the patent's abstract states, relates to an siRNA between 23 and 27 nucleotides that inhibits the expression of ZFAT in order to decrease cell proliferation of cancer cells, induce apoptosis of cancer cells, or inhibit an immunoresponse. "The inhibitory RNA of this invention is useful for development of molecular target agents particularly for cancer cells or immunosuppressive agents."

Title: Genetic Inhibition by Double-Stranded RNA

Patent Number: 8,580,754

Filed: Oct. 1, 2007

Lead Inventor: Andrew Fire, Carnegie Institution of Washington

The patent, its abstract states, claims "a process … of introducing an RNA into a living cell to inhibit gene expression of a target gene in that cell. The process may be practiced ex vivo or in vivo. The RNA has a region with double-stranded structure. Inhibition is sequence-specific in that the nucleotide sequences of the duplex region of the RNA and of a portion of the target gene are identical."

Title: Short Oligomer Antagonist Compounds for the Modulation of Target mRNA

Patent Number: 8,580,756

Filed: March 19, 2008

Lead Inventor: Jens Bo Rode Hansen, Santaris Pharma

The invention provides "LNA gapmer oligomers of between 10 [and] 20 nucleobases in length, which have a total of [one to three] phosphodiester internucleoside linkages," the patent's abstract states. "Such oligomers have been found to have superior bioavailability and have also been found to selectively accumulate in kidney cells."

Title: Anti-hepatitis C Virus Composition

Patent Number: 8,580,759

Filed: Aug. 28, 2009

Lead Inventor: Kohji Moriishi, Osaka University

The invention provides an "anti-hepatitis C virus composition that includes a substance that suppresses the expression or function of a PA28-gamma gene, a method for preventing hepatitis C viral infection or suppressing hepatitis C virus growth that includes the step of administering the composition to a subject, and a method for screening an effective component of an anti-hepatitis C virus composition that includes the step of selecting a substance that inhibits the expression or function of a PA28-gamma gene," according to the patent's abstract.

The patent specifically claims an siRNA or shRNA that inhibits PA28-gamma.

Title: Multi-conjugate of siRNA and Preparing Method Thereof

Patent Number: 8,580,946

Filed: April 29, 2009

Lead Inventor: Tae Gwan Park, Korea Advanced Institute of Science and Technology

The invention, the patent's abstract states, relates to a "multi-conjugate of siRNA prepared by direct binding of double-stranded sense/antisense siRNA monomers or indirect covalent bonding mediated by a cross-linking agent or a polymer, and a preparing method of the same. The preparing method of an siRNA multi-conjugate … is characterized by simple and efficient reaction and thereby the prepared siRNA multi-conjugate … has high molecular weight multiple times the conventional siRNA, so that it has high negative charge density, suggesting that it has excellent ionic interaction with a cationic gene carrier, and high gene delivery efficiency."

Title: Methods and Materials for Conferring Resistance to Pests and Pathogens of Plants

Patent Number: 8,581,039

Filed: June 28, 2011

Inventor: Charles Niblett, Venganza

The patent, its abstract states, claims "methods and materials for conferring pest resistance to plants. … Plants are transformed with a silencing construct homologous to a gene of a plant pest that is essential for the survival, development, or pathogenicity of the pest. This results in the plant producing RNAi to the selected gene, which, when ingested by the pest results in silencing of the gene and a subsequent reduction of the pest's ability to harm the plant. In other embodiments, the pest's reduced ability to harm the plant is passed on to pest progeny."